Abbott's Esprit BTK Dissolvable Stent Approved By Health Canada
I'm PortAI, I can summarize articles.
雅培已獲得加拿大衞生部批准其 Esprit BTK 依維莫司釋放可吸收支架系統，該可溶支架旨在治療膝下慢性肢體威脅缺血（CLTI）。該設備有助於保持動脈通暢，並釋放藥物依維莫司以促進癒合，直至其完全溶解，滿足超過 80 萬名患有外周動脈疾病（PAD）的加拿大人的需求
雅培（Abbott Laboratories，股票代碼：ABT）週一宣佈，加拿大衞生部已批准其可溶解支架——Esprit BTK Everolimus Eluting Resorbable Scaffold System。
該設備用於治療下肢慢性威脅性缺血（CLTI）患者。它可以保持動脈通暢，並釋放藥物依維莫司，以支持在支架完全溶解之前的癒合。
超過 80 萬加拿大人患有周圍動脈疾病（PAD）。CLTI 是 PAD 的一種嚴重形式，動脈因斑塊堵塞而阻礙血液和氧氣流向小腿和腳部。CLTI 患者常常經歷劇烈疼痛和難以癒合的開放性傷口。
如需評論和反饋，請聯繫：editorial@rttnews.com
商業新聞
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments